Received: 23 October 2015
Revised: 13 May 2016
Accepted: 4 September 2016
DOI 10.1002/dmrr.2858
RESEARCH ARTICLE
A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin Denis Raccah1 | Engels Chou2 | Stephen Colagiuri3 | Zsolt Gaàl4 | Fernando Lavalle5 Ashot Mkrtumyan6 | Elena Nikonova7 | Nikolaos Tentolouris8 | Josep Vidal9 |
|
Melanie Davies10 1
Department of Diabetology, University Hospital Sainte‐Marguerite, Marseille, France
Abstract
2
Background
Sanofi R&D, Bridgewater, NJ, USA
3
Boden Institute, University of Sydney, Camperdown, NSW, Australia
4
the initiation of basal insulin therapy in Europe, Asia Pacific, the United States, and Latin
Department of Medicine, András Jósa Teaching Hospital, Nyíregyháza, Hungary
America.
5
Methods
Servicio de Endocrinología, Facultad de Medicina UANL, Hospital Universitario, Monterrey, NL, Mexico
6
Moscow State Medical and Stomatological University named after Evdokimov, Moscow, Russian Federation
7
Sanofi Global Medical Affairs, Bridgewater, NJ, USA
8
University of Athens Medical School, Athens, Greece
9
Endocrinology and Nutrition Department, Hospital Clinic, Barcelona, Spain
10
Diabetes Research Centre, University of Leicester, Leicester, United Kingdom Correspondence Denis Raccah, Department of Diabetology, University Hospital Sainte‐Marguerite, 270 Boulevard de Sainte‐Marguerite, 13009 Marseille, France. Email: denis.raccah@ap‐hm.fr
This study used data from different sources to identify the extent of the unmet
need for postprandial glycemic control in patients with type 2 diabetes mellitus (T2DM) after
Different levels of evidence were used as available for each country/region, with
data extracted from seven randomized controlled trials (RCTs), three clinical trial registries (CTRs), and three electronic medical record (EMR) databases. Glycemic status was categorized as “well controlled” (glycated hemoglobin [HbA1c] at target [
Revised: 13 May 2016
Accepted: 4 September 2016
DOI 10.1002/dmrr.2858
RESEARCH ARTICLE
A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin Denis Raccah1 | Engels Chou2 | Stephen Colagiuri3 | Zsolt Gaàl4 | Fernando Lavalle5 Ashot Mkrtumyan6 | Elena Nikonova7 | Nikolaos Tentolouris8 | Josep Vidal9 |
|
Melanie Davies10 1
Department of Diabetology, University Hospital Sainte‐Marguerite, Marseille, France
Abstract
2
Background
Sanofi R&D, Bridgewater, NJ, USA
3
Boden Institute, University of Sydney, Camperdown, NSW, Australia
4
the initiation of basal insulin therapy in Europe, Asia Pacific, the United States, and Latin
Department of Medicine, András Jósa Teaching Hospital, Nyíregyháza, Hungary
America.
5
Methods
Servicio de Endocrinología, Facultad de Medicina UANL, Hospital Universitario, Monterrey, NL, Mexico
6
Moscow State Medical and Stomatological University named after Evdokimov, Moscow, Russian Federation
7
Sanofi Global Medical Affairs, Bridgewater, NJ, USA
8
University of Athens Medical School, Athens, Greece
9
Endocrinology and Nutrition Department, Hospital Clinic, Barcelona, Spain
10
Diabetes Research Centre, University of Leicester, Leicester, United Kingdom Correspondence Denis Raccah, Department of Diabetology, University Hospital Sainte‐Marguerite, 270 Boulevard de Sainte‐Marguerite, 13009 Marseille, France. Email: denis.raccah@ap‐hm.fr
This study used data from different sources to identify the extent of the unmet
need for postprandial glycemic control in patients with type 2 diabetes mellitus (T2DM) after
Different levels of evidence were used as available for each country/region, with
data extracted from seven randomized controlled trials (RCTs), three clinical trial registries (CTRs), and three electronic medical record (EMR) databases. Glycemic status was categorized as “well controlled” (glycated hemoglobin [HbA1c] at target [
